A Switch in Hepatic Cortisol Metabolism across the Spectrum of Non Alcoholic Fatty Liver Disease

The 11- -Hydroxysteroid Dehydrogenase Type 1 Inhibitor INCB13739 Improves Hyperglycemia in Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy

(2010) J. Rosenstock et al.   DIABETES CARE

Increased 5α-Reductase Activity and Adrenocortical Drive in Women with Polycystic Ovary Syndrome

(2009) Dimitra A. Vassiliadi et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Induction of hepatic 11β-hydroxysteroid dehydrogenase type 1 in patients with alcoholic liver disease

(2008) Adeeba Ahmed et al.   CLINICAL ENDOCRINOLOGY

Hepatic 11beta-HSD1 mRNA expression in fatty liver and nonalcoholic steatohepatitis

(2008) Sarah Konopelska et al.   CLINICAL ENDOCRINOLOGY

Reduced Glucocorticoid Production Rate, Decreased 5 -Reductase Activity, and Adipose Tissue Insulin Sensitization After Weight Loss

(2008) J. W. Tomlinson et al.   DIABETES

A novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis

(2008) I J Bujalska et al.   JOURNAL OF ENDOCRINOLOGY

Non-alcoholic fatty liver disease: The mist gradually clears

(2008) Nimantha Mark Wilfred de Alwis et al.   JOURNAL OF HEPATOLOGY

Macrophages in Hepatitis B and Hepatitis C Virus Infections

(2008) M. Heydtmann   JOURNAL OF VIROLOGY

The role and regulation of 11β-hydroxysteroid dehydrogenase type 1 in the inflammatory response

(2008) Karen E. Chapman et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY